Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression
This open-label study (n=97) on patients with unipolar and bipolar depression examined the effects of six repeated ketamine infusions. Significant and sustained improvements in depression and suicidal ideation were observed, with response and remission rates at 68.0% and 50.5%, respectively. The treatment was effective and safe, demonstrating rapid antidepressant and antisuicidal effects. Positive response factors included early response, higher income, and no prior psychiatric hospitalization.
Authors
- Yuping Ning
- Wei Zheng
- Yanling Zhou
Published
Abstract
Objective
Single-dose intravenous (IV) injection of ketamine has shown rapid but transient antidepressant effects. The strategy of repeated-dose ketamine infusions to maintain antidepressant effects has received little systematic study. This study was conducted to examine the efficacy and tolerability of six ketamine infusions in Chinese patients with unipolar and bipolar depression.
Methods
Ninety seven patients with unipolar (n = 77) and bipolar (n = 20) depression received repeated ketamine infusions (0.5 mg/kg over 40 min) with continuous vital sign monitoring. Depressive symptoms were measured by the Montgomery-Asberg Depression Rating Scale (MADRS). Suicidal ideation was assessed using the Scale for Suicidal Ideations (SSI)-part 1. Anxiety symptoms were evaluated with the 14-item Hamilton Anxiety Scale (HAMA). Adverse psychopathological and dissociative effects were assessed using the Brief Psychiatric Rating Scale (BPRS)-positive symptoms and Clinician Administered Dissociative States Scale (CADSS), respectively. Patients were assessed at baseline, 4 and 24 h, and 3, 4, 5, 6, 8, 9, 10, 11, 12, 13 and 26 days.
Results
After six ketamine infusions, the response and remission rates were 68.0% and 50.5%, respectively. There were significant decreases in MADRS, SSI-part 1, and HAMA scores within four hours following the first ketamine infusion, and the decreases were sustained over the subsequent infusion period. The nonresponder subgroup manifested rapid significant improvement in suicidal ideations throughout the course of treatment. After the six ketamine infusions, the response was positively associated with the response at 24 h after the first infusion (OR = 8.94), personal income ≥4000 yuan/month (OR = 3.04), and no history of psychiatric hospitalization (OR = 3.41). Only CADSS scores had a mild but marginally significant increase after the first infusion but with a significant BPRS score decrease.
Conclusion
Six ketamine infusions were safe and effective in patients with unipolar and bipolar depression. The rapid and robust antidepressant and antisuicidal effects of ketamine infusion within four hours were sustained following the subsequent infusions.
Research Summary of 'Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression'
Introduction
Mood disorders carry high personal and societal burden, and available antidepressant treatments typically take more than two weeks to produce clinically meaningful benefit, which prolongs the period of elevated suicidal risk. Electroconvulsive therapy produces faster antidepressant and antisuicidal effects but is limited by invasiveness and cognitive adverse effects. Earlier research implicates glutamatergic mechanisms and has shown that a single subanaesthetic IV infusion of ketamine (0.5 mg/kg) produces rapid antidepressant and antisuicidal effects in unipolar and bipolar depression, but these benefits frequently wane within days to around two weeks. This study aimed to examine whether a repeated‑dose ketamine protocol (six IV infusions of 0.5 mg/kg over 40 minutes, given on a Monday–Wednesday–Friday schedule across 12 days) would produce rapid and sustained antidepressant and antisuicidal effects in Chinese patients with unipolar or bipolar depression. Zheng and colleagues hypothesised that the regimen would be tolerable and that early therapeutic effects would be maintained across subsequent infusions.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- Authors
- APA Citation
Zheng, W., Zhou, Y., Liu, W., Wang, C., Zhan, Y., Li, H., Chen, L., Li, M. D., & Ning, Y. (2018). Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression. Journal of Psychiatric Research, 106, 61-68. https://doi.org/10.1016/j.jpsychires.2018.09.013
References (7)
Papers cited by this study that are also in Blossom
Ionescu, D. F., Vande Voort, J. L., Niciu, M. J. et al. · Journal of Psychiatric Research (2014)
Berman, R. M., Cappiello, A., Anand, A. et al. · Biological Psychiatry (2000)
Glue, P., Medlicott, N. J., Harland, S. et al. · Journal of Psychopharmacology (2017)
Kishimoto, T., Chawla, J. M., Hagi, K. et al. · Psychological Medicine (2016)
Vande Voort, J. L., Ballard, E. D., Luckenbaugh, D. A. et al. · Journal of Clinical Psychiatry (2017)
Wilkinson, S. T., Ballard, E. D., Bloch, M. H. et al. · American Journal of Psychiatry (2017)
Zarate, C. A., Brutsche, N. E., Ibrahim, L. et al. · Biological Psychiatry (2012)
Cited By (16)
Papers in Blossom that reference this study
Zhou, Y., Lan, X-F., Wang, C. et al. · Child and Adolescent Psychiatry (2024)
Lan, X-F., Wang, C-Y., Zhang, F. et al. · Child and Adolescent Psychiatry (2023)
Wu, Z., Gan, Y., Li, N. et al. · Journal of Affective Disorders (2023)
Wang, C., Lan, X-F., Zhou, Y. · Frontiers in Neuroscience (2023)
McIntyre, R. S. · Bipolar Disorders An International Journal of Psychiatry and Neurosciences (2023)
Ning, Y-P., Zheng, W., Yang, X-H. et al. · Frontiers in Psychiatry (2022)
Zheng, W., Yang, X. H., Gu, L. M. et al. · Journal of Affective Disorders (2022)
Zhou, Y-L., Wang, C., Lan, X-F. et al. · Frontiers in Psychiatry (2022)
Zheng, W., Gu, L. M., Sun, C. H. et al. · Journal of Affective Disorders (2022)
Zhou, Y-L., Wang, C., Lan, X-F. et al. · Journal of Psychiatric Research (2021)
Show all 16 papersShow fewer
Kopra, E., Mondelli, V., Pariante, C. et al. · Journal of Psychopharmacology (2021)
Zheng, W., Zhou, Y. L., Wang, C. Y. et al. · PeerJ (2021)
Wilkowska, A., Szałach, L., Cubała, W. J. · Neuropsychiatric Disease And Treatment (2020)
Jelen, L. A., Young, A. H., Stone, J. M. · Journal of Psychopharmacology (2020)
Hashimoto, K. · Psychiatry and Clinical Neurosciences (2019)
Zheng, W., Zhou, Y-L., Wang, C-Y. · Journal of Psychopharmacology (2019)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.